The objective of this grant opportunity is to support new, adaptive platform trials (Phase 2 or 3) in areas of unmet clinical need. The platform must be internationally collaborative, with joint project leads based in Australia (for the Australian-based component of the trial) and the UK (for the UK-based component of the trial).